The mutation of hepatic lipase gene is the main reason affecting the synthesis and activity changes of HL.
肝脂酶基因（L IPC）变异是影响HL合成、活性改变的主要原因。
Objective To study the interaction between hepatic lipase gene-250G/A polymorphism and combined hyperlipidemia.
目的：探讨混合型高脂血症与肝脂酶基因启动子250G/A多态性的关系。
Objective To study the new approach for rapid screening of active ingredients from Chinese medicine regulating hepatic lipase activities.
目的研究快速筛选调节肝脂酶活性中药成分的方法。
Conclusions Reduced activity of lipoprotein lipase and hepatic lipase is one of causes leading to hypertriglyceridemia in nephrotic syndrome.
结论肾病综合征脂蛋白脂酶和肝脂酶活性降低为高三酰甘油血症的病因之一。
Methods Rat liver homogenate and colorimetric assay of hepatic lipase (HL) activities were used to investigate the effects of different components of Chinese medicine on hepatic lipase activities.
方法利用大鼠肝组织匀浆和比色法检测肝脂酶(HL)活性，观察不同实验条件及中药成分对HL活性的影响。
Context: Hepatic lipase influences metabolism of high-density lipoprotein (HDL), a risk factor for ischemic cardiovascular disease (ICD: ischemic heart disease and ischemic cerebrovascular disease).
背景：肝脂肪酶影响缺血性心血管病（ICD：缺血性心脏病及缺血性脑血管病）的危险因子HDL的代谢。
Context: Hepatic lipase influences metabolism of high-density lipoprotein (HDL), a risk factor for ischemic cardiovascular disease (ICD: ischemic heart disease and ischemic cerebrovascular disease).
背景：肝脂肪酶影响缺血性心血管病（ICD：缺血性心脏病及缺血性脑血管病）的危险因子HDL的代谢。
应用推荐